US · Healthcare · Medical Instruments & Supplies
EPS came in at -0.22 against a street estimate of -0.21 — a miss of 4.8%.
Analysts rate Harvard Bioscience Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $7.50.
| Fund | Stake |
|---|---|
| Weber Capital Management LLC | 6.83% |
| Meros Investment Management, LP | 4.02% |
| Acadian Asset Management LLC | 3.95% |
| Vanguard Capital Management, LLC | 3.73% |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 3.14% |
| Corsair Capital Management LLC | 2.70% |
| Two Sigma Investments LLC | 2.52% |
| Renaissance Technologies Corp | 2.18% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Harvard Bioscience Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.